ArchivesMagazine - 20 May 2021Buy Shield Therapeutics as it stands on cusp of US breakthrough Iron deficiency drug Accrufer could generate hundreds of millions in revenue in the coming years 20 May 2021|Great Ideas|by Martin Gamble Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < This year’s UK IPOs reward investors despite Deliveroo and Alphawave flops Bank a tidy profit on UDG as private equity swoops > Issue: 20 May 2021 - Page 10 | Contents Next: Bank a tidy profit on UDG as private equity swoops Previous: This year’s UK IPOs reward investors despite Deliveroo and Alphawave flops Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Martin Gamble Issue Contents Ask Tom Should I use a SIPP or an ISA for retirement savings? Case study Investor diary: looking for value and growth Editor's View Bitcoin’s entry into the mainstream is proving short-lived Feature US vs China - which is best for investors and where should you put your money? Covid-19 diagnostic firms have fallen too far given they still play a crucial role The case for and against share buybacks Funds The value funds vying for top dog status Great Ideas Buy Shield Therapeutics as it stands on cusp of US breakthrough Hill & Smith set to cash in on US infrastructure boom Investors toast Diageo’s £4.5 billion capital return Coca-Cola HBC should fizz higher on reopening Improving backdrop for still cheap TT Electronics Bank a tidy profit on UDG as private equity swoops Investment Trusts How to analyse property-focused investment trusts, aka REITs News Indian Covid strain a threat to hospitality and travel sectors UK stocks slump as inflation doubles in April This year’s UK IPOs reward investors despite Deliveroo and Alphawave flops Is good news on the UK property surge now priced into housebuilders? Personal Finance Protecting your pension income from inflation Russ Mould Commodities remain central to the FTSE 100
